Elexacaftor, Ivacaftor, Tezacaftor; Ivacaftor Patent Expiration
Elexacaftor, Ivacaftor, Tezacaftor; Ivacaftor is used for treating cystic fibrosis in patients with specific genetic mutations. It was first introduced by Vertex Pharmaceuticals Inc
Elexacaftor, Ivacaftor, Tezacaftor; Ivacaftor Patents
Given below is the list of patents protecting Elexacaftor, Ivacaftor, Tezacaftor; Ivacaftor, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Trikafta (copackaged) | US10793547 | Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator | Dec 08, 2037 | Vertex Pharms Inc |
| Trikafta (copackaged) | US11179367 | Pharmaceutical compositions for treating cystic fibrosis | Dec 08, 2037 | Vertex Pharms Inc |
| Trikafta (copackaged) | US11453655 | Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator | Dec 08, 2037 | Vertex Pharms Inc |
| Trikafta (copackaged) | US11517564 | Methods of treatment for cystic fibrosis | Dec 08, 2037 | Vertex Pharms Inc |
| Trikafta (copackaged) | US10758534 | NA | Oct 06, 2035 | Vertex Pharms Inc |
| Trikafta (copackaged) | US11426407 | Modulators of cystic fibrosis transmembrane conductance regulator | Oct 06, 2035 | Vertex Pharms Inc |
| Trikafta (copackaged) | US9012496 | Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof | Jul 15, 2033 | Vertex Pharms Inc |
| Trikafta (copackaged) | US10272046 | Pharmaceutical composition and administrations thereof | Feb 27, 2033 | Vertex Pharms Inc |
| Trikafta (copackaged) | US11147770 | Pharmaceutical composition and administrations thereof | Feb 27, 2033 | Vertex Pharms Inc |
| Trikafta (copackaged) | US11752106 | Pharmaceutical composition and administrations thereof | Feb 27, 2033 | Vertex Pharms Inc |
| Trikafta (copackaged) | US8883206 | Pharmaceutical composition and administrations thereof | Feb 27, 2033 | Vertex Pharms Inc |
| Trikafta (copackaged) | US10081621 | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide | Mar 25, 2031 | Vertex Pharms Inc |
| Trikafta (copackaged) | US11578062 | Solid forms of (R)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide | Mar 25, 2031 | Vertex Pharms Inc |
| Trikafta (copackaged) | US10646481 | Pharmaceutical composition and administrations thereof | Aug 13, 2029 | Vertex Pharms Inc |
| Trikafta (copackaged) | US11564916 | Pharmaceutical composition and administrations thereof | Aug 13, 2029 | Vertex Pharms Inc |
| Trikafta (copackaged) | US8415387 | Modulators of ATP-binding cassette transporters | Nov 12, 2027 | Vertex Pharms Inc |
| Trikafta (copackaged) | US8324242 | Modulators of ATP-binding cassette transporters | Aug 05, 2027 | Vertex Pharms Inc |
| Trikafta (copackaged) | US7776905 | Modulators of ATP-binding cassette transporters | Jun 03, 2027 | Vertex Pharms Inc |
| Trikafta (copackaged) | US7495103 | Modulators of ATP-binding cassette transporters | May 20, 2027 | Vertex Pharms Inc |
| Trikafta (copackaged) | US7645789 | Indole derivatives as CFTR modulators | May 01, 2027 | Vertex Pharms Inc |
| Trikafta (copackaged) | US8598181 | Modulators of ATP-binding cassette transporters | May 01, 2027 | Vertex Pharms Inc |
| Trikafta (copackaged) | US8623905 | Modulators of ATP-binding cassette transporters | May 01, 2027 | Vertex Pharms Inc |
| Trikafta (copackaged) | US10022352 | Modulators of ATP-binding cassette transporters | Apr 09, 2027 | Vertex Pharms Inc |
| Trikafta (copackaged) | US10239867 | Modulators of ATP-binding cassette transporters | Apr 09, 2027 | Vertex Pharms Inc |
| Trikafta (copackaged) | US11639347 | Modulators of ATP-binding cassette transporters | Apr 09, 2027 | Vertex Pharms Inc |
| Trikafta (copackaged) | US9974781 | Modulators of ATP-binding cassette transporters | Apr 09, 2027 | Vertex Pharms Inc |
| Trikafta (copackaged) | US8410274 | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide | Dec 28, 2026 | Vertex Pharms Inc |
| Trikafta (copackaged) | US8754224 | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide | Dec 28, 2026 | Vertex Pharms Inc |
| Trikafta (copackaged) | US9670163 | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide | Dec 28, 2026 | Vertex Pharms Inc |
| Trikafta (copackaged) | US9931334 | Solid forms of N[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide | Dec 28, 2026 | Vertex Pharms Inc |
| Trikafta (copackaged) | US8354427 | Modulators of ATP-binding cassette transporters | Jul 06, 2026 | Vertex Pharms Inc |
| Trikafta (copackaged) | US8629162 | Modulators of ATP-binding cassette transporters | Jun 24, 2025 | Vertex Pharms Inc |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Elexacaftor, Ivacaftor, Tezacaftor; Ivacaftor's patents.
Latest Legal Activities on Elexacaftor, Ivacaftor, Tezacaftor; Ivacaftor's Patents
Given below is the list recent legal activities going on the following patents of Elexacaftor, Ivacaftor, Tezacaftor; Ivacaftor.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 08 Apr, 2024 | US10793547 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 01 Mar, 2024 | US10758534 |
| Electronic Review Critical | 24 May, 2023 | US11578062 |
| Post Issue Communication - Certificate of Correction | 05 May, 2023 | US11578062 |
| Electronic Review Critical | 03 May, 2023 | US11639347 |
| Email Notification Critical | 03 May, 2023 | US11639347 |
| Patent Issue Date Used in PTA Calculation Critical | 02 May, 2023 | US11639347 |
| Miscellaneous Communication to Applicant - No Action Count | 02 May, 2023 | US11639347 |
| Mail Miscellaneous Communication to Applicant | 02 May, 2023 | US11639347 |
| Recordation of Patent eGrant | 02 May, 2023 | US11639347 |
Elexacaftor, Ivacaftor, Tezacaftor; Ivacaftor's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List